Last --
Change Today 0.00 / 0.00%
Volume 0.0
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Open
--
Previous Close
$59,660
Day High
--
Day Low
--
52 Week High
04/1/14 - $62,700
52 Week Low
08/1/14 - $54,800
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
6.3B
EX-Date
02/4/15
P/E TM
--
Dividend
$1.12
Dividend Yield
3.45%
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd.; and strategic collaboration with iTeos Therapeutics SA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

77,700 Employees
Last Reported Date: 02/28/14
Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFE) Key Developments

Pfizer Inc. Announces Presentation of Early- and Late-Stage Data from Clinical Studies

Pfizer Inc. announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate (ADC) MYLOTARG (gemtuzumab ozogamicin) in select adult AML populations. Oral and poster presentations focused on the efficacy of MYLOTARG in previously untreated patients with AML. Two oral presentations included: AML-19 (abstract #619 [1]): This investigator-led, randomized, Phase 3 study (N=237) found that MYLOTARG significantly improved overall survival (OS) in elderly patients with AML not considered fit for intensive chemotherapy, compared to best supportive care (BSC). The study was conducted by the European Organization for the Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) leukemia groups.

Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B with Pfizer Inc

Spark Therapeutics announced that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B. The companies will work together on a worldwide basis with the aim of bringing an important investigational therapy to patients. Hemophilia B is a rare genetic blood disorder that affects approximately 4,000 males in the U.S. and 26,000 males worldwide. Current treatment requires recurrent intravenous infusions of either plasma-derived or recombinant Factor IX to control bleeding episodes. Spark's proprietary, bioengineered vectors are designed to deliver a high-activity Factor IX gene to patients, enabling endogenous production of Factor IX, with the potential to be effective for a number of years. This program leverages a long track record of hemophilia B gene therapy research and clinical development conducted by Spark and its founding scientific team over the past two decades. Under the terms of the agreement, Spark will receive an upfront payment of $20 million and will be eligible for additional development and commercialization milestone payments of up to $260 million for multiple hemophilia B product candidates that may be developed under the collaboration. Spark will be responsible for conducting all Phase 1/2 studies while Pfizer will assume responsibility for pivotal studies, any regulatory approvals and potential global commercialization of the product. Spark is entitled to receive double-digit royalties based on global product sales.

iTeos Therapeutics SA Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets

iTeos Therapeutics SA announced a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. Additionally, the parties will collaborate to discover and validate new targets that play key roles in the ability of tumors to evade immune responses. These new targets will be shared by iTeos and Pfizer for further independent or collaborative development. iTeos will receive from Pfizer an up-front payment of EUR 24 million, plus an equity investment, licensing fees and collaborative funding. Further, iTeos will be eligible to earn potential milestone payments from Pfizer based on the achievement of specific development, regulatory and commercial milestones across the IDO1 and TDO2 programs, in addition to royalties on sales. iTeos also has the opportunity to earn additional milestone and royalty payments for any of the new target programs that are advanced by Pfizer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:CB $0.00 COP 0.00

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $165.48 USD +0.18
Bayer AG €114.01 EUR -1.39
Gilead Sciences Inc $108.45 USD +2.91
Novartis AG SFr.93.05 CHF +0.95
Procter & Gamble Co/The $92.05 USD +0.05
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 19.7x
Price/Sales 4.0x
Price/Book 2.6x
Price/Cash Flow 13.7x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.